Carboplatin plus pemetrexed for platinum-pretreated, advanced non-small cell lung cancer: a retrospective study with pharmacogenetic evaluation.
about
XRCC3 Thr241Met polymorphism and clinical outcomes of NSCLC patients receiving platinum-based chemotherapy: a systematic review and meta-analysisRNA silencing of integrin-linked kinase increases the sensitivity of the A549 lung cancer cell line to cisplatin and promotes its apoptosis.Inhibition of BRCA2 and Thymidylate Synthase Creates Multidrug Sensitive Tumor Cells via the Induction of Combined "Complementary Lethality".Pharmacogenomics of platinum-based chemotherapy sensitivity in NSCLC: toward precision medicine.Xeroderma pigmentosum complementation group D polymorphism toward lung cancer susceptibility survival and response in patients treated with platinum chemotherapy.Correlation of genetic polymorphisms with clinical outcomes in pemetrexed-treated advanced lung adenocarcinoma patients.
P2860
Carboplatin plus pemetrexed for platinum-pretreated, advanced non-small cell lung cancer: a retrospective study with pharmacogenetic evaluation.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Carboplatin plus pemetrexed fo ...... th pharmacogenetic evaluation.
@en
Carboplatin plus pemetrexed fo ...... th pharmacogenetic evaluation.
@nl
type
label
Carboplatin plus pemetrexed fo ...... th pharmacogenetic evaluation.
@en
Carboplatin plus pemetrexed fo ...... th pharmacogenetic evaluation.
@nl
prefLabel
Carboplatin plus pemetrexed fo ...... th pharmacogenetic evaluation.
@en
Carboplatin plus pemetrexed fo ...... th pharmacogenetic evaluation.
@nl
P2093
P2860
P1476
Carboplatin plus pemetrexed fo ...... th pharmacogenetic evaluation.
@en
P2093
D Giuffrida
F R Tofanetti
Giulio Metro
L Marcomigni
M Ferraldeschi
M J Fischer
P2860
P2888
P304
P356
10.1007/S00280-011-1632-X
P577
2011-04-06T00:00:00Z